The development of novel T cell therapies to target leukemia has facilitated the translation of
this approach for hematologic malignancies. Different methods of manufacturing leukemia-specific T
cells have evolved, along with additional measures to increase the safety of this therapy. This is an
overview of expanded T cell therapeutics with a focus on how the manufacturing strategies have been
refined, and where the research is heading.